Merck has received approval for Ervebo, the first F
vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older.
Cases of EVD are very rare in the U.S., only acquired by individuals in other countries who then traveled to the U.S., or health care workers who became ill after treating patients with EVD.
“While the risk of Ebola virus disease in the U.S. remains low, the U.S. government remains deeply committed to fighting devastating Ebola outbreaks in Africa, including the current outbreak in the Democratic Republic of the Congo,” said Anna Abram, FDA Deputy Commissioner for Policy, Legislation, and International Affairs.